Publication number: 20160339074
Abstract: The present invention is directed to compositions comprising the HCV NS3/4A inhibitor, (1aR,5S,8S,10R,22aR)-5-tert-butyl-N-{(1R,2S)-1-[(cyclopropylsulfonyl)carbamoyl]-2-ethenylcyclopro-pyl}-14-methoxy-3,6-dioxo-1,1a,3,4,5,6,9,10,18,19,20,21,22,22a-tetradecahydro-8H-7,10-methanocyclopropa[18,19][1,10,3,6]dioxa-diazacyclononadecino[11,12-b]quinoxaline-8-carboxamide, or a pharmaceutically acceptable salt thererof, an oral absorption enhancing polymer, and, optionally, a surfactant. The present invention is also directed to solid dispersions and pharmaceutical compositions containing or made from these compositions, and the methods for making these solid dispersions and pharmaceutical compositions.
Type:
Application
Filed:
February 3, 2015
Publication date:
November 24, 2016
Applicant:
Merck Sharp & Dohme Corp.
Inventors:
Melanie J. Marota, Craig McKelvey, Nicholas Birringer, Jesse Kuiper, Paul A. Harmon, Adam J. Socia, Patrick Jules Marsac, Stephen L. Conway